Unisia

Quick links to important sections

Unisia

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unisia

Quick Facts

Property Description
Active Ingredients Amlodipine, Candesartan
Form Fixed-dose combination (FDC) tablet
Pharmacological Class Antihypertensive (CCB and ARB)
Common Therapeutic Use Management of high blood pressure
Origin Synthetic

What is Unisia and Its Pharmacological Identity?

Unisia is a synthetic, fixed-dose combination (FDC) tablet, defined as an antihypertensive agent within the field of cardiovascular medicine. It is a Prescription-only medicine (POM) that combines two distinct active components into a single oral dosage form. This FDC structure is utilized for addressing essential hypertension as a therapeutic strategy. This pharmaceutical approach is intended to provide consistent management of high blood pressure.

Composition: A Dual-Action Combination Tablet

The composition includes Amlodipine, which is classified as a dihydropyridine Calcium Channel Blocker (CCB), and Candesartan, which belongs to the class of Angiotensin II Receptor Blockers (ARBs). The single-pill combination merges two separate drug classes that are frequently co-administered but are delivered here in a precise, pre-set ratio. The compounds are incorporated as their stable salt forms, Amlodipine besilate and Candesartan cilexetil, to ensure consistent delivery within the tablet matrix.

How Does the Combination Provide a Synergistic Effect?

The formulation is designed to address blood pressure via two independent, yet complementary, physiological mechanisms. The Amlodipine component primarily causes direct vasodilation, encouraging arteries to widen blood vessels. Conversely, the Candesartan component performs Angiotensin II antagonism, working specifically to block a chemical signal that naturally constricts arteries. This coordinated action is intended to achieve blood pressure control by reducing peripheral vascular resistance, serving the drug's core therapeutic purpose.

What side effects are possible with Unisia?

Possible side effects and safety information

The safety profile of Unisia, a fixed-dose combination of Amlodipine and Candesartan, is derived from the official regulatory documentation of its two active components, encompassing adverse reactions categorized by frequency and body system.

Classification Representative Side Effects Affected System-Organ Class
Common Swelling/Edema (often dose-related), Headache, Fatigue, Nausea, Dizziness Vascular, Nervous System, General
Post-Marketing Angioedema, Severe Hepatic Function Disorder (Jaundice/Hepatitis), Pancreatitis Skin/Subcutaneous Tissue, Hepato-biliary, Gastrointestinal

Serious adverse reactions are explicitly documented in regulatory warnings. These include the potential for Angioedema (severe swelling of the face, lips, or throat) related to the Candesartan component. The Amlodipine component carries a documented risk of Worsening Angina or Acute Myocardial Infarction upon treatment initiation or dose increase, particularly in individuals with severe coronary artery disease. Symptomatic Hypotension (low blood pressure) is also noted as a risk.

Population-Specific Safety Constraints

The medicine is strictly contraindicated in pregnancy due to the risk of fetal harm and toxicity associated with the Candesartan component. Use also requires specific caution in patients with severe hepatic impairment due to the extensive liver metabolism of Amlodipine. Additionally, Candesartan carries a high-level safety warning regarding an increased risk of hyperkalemia (high potassium levels) and renal impairment when used concurrently with other Renin-Angiotensin System inhibitors.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Unisia (Amlodipine/Candesartan) is primarily defined by the marked hypotension and excessive peripheral vasodilation documented in regulatory prescribing information. Severe exposure may lead to life-threatening outcomes including profound shock, potential acute myocardial infarction in susceptible patients, and acute renal failure due to the effects of the combination.

Official Emergency Actions and Management

Regulatory authorities mandate that individuals seek immediate medical attention for any suspected overdose due to the risk of severe cardiovascular collapse. If symptomatic hypotension or severe signs occur, emergency help must be contacted immediately.

Management is centered on specific supportive measures, as no specific antidote is known for either component. Procedures include the initiation of active cardiac and respiratory monitoring, providing cardiovascular support, and judiciously administering intravenous fluids.

For refractory low blood pressure, the use of vasopressors may be warranted. Labeling also notes that neither the Amlodipine nor the Candesartan component is expected to be effectively removed by hemodialysis due to high protein binding.

Population-Specific Considerations

Increased risk of severe outcomes is documented for elderly patients and patients with hepatic impairment or pre-existing renal disease. Periodic monitoring of serum potassium and creatinine levels is required during overdose management.

Therapeutic Uses of Unisia

Unisia: Main Uses and Benefits

Quick Facts
Primary Therapeutic Domains
Helps manage elevated blood pressure (hypertension)
Assists in supporting cardiovascular function

Unisia is a medication approved to assist in the management of high blood pressure, medically known as hypertension. It is intended for use in adult patients whose condition requires controlled blood pressure to help support overall cardiovascular function.

Management of hypertension is essential to potentially reduce the risk of serious health events. Unisia works to facilitate the maintenance of blood pressure within a target range when used as part of a comprehensive treatment plan that may include lifestyle modifications.

Patients should always follow the guidance of a qualified healthcare professional regarding their therapeutic regimen and intended outcomes. A complete understanding of approved uses and safety considerations is available through professional consultation and official prescribing information.

The medication is utilized to help achieve and sustain blood pressure control over time, thereby offering a therapeutic benefit in managing this chronic condition. It is not intended to treat conditions outside of its approved indications.

Eligibility and Restrictions for Use

The eligibility for Unisia is strictly defined by regulatory authorities and is intended only for adult patients whose high blood pressure is not adequately controlled by single-agent therapy. The following classifications dictate who must not use the medicine and who requires conditional use based on pre-existing health status.

Classification Official Regulatory Status
Contraindicated Populations Absolute prohibition for individuals with known hypersensitivity to either component (Amlodipine or Candesartan), a history of angioedema related to prior ARB or ACE inhibitor use, or severe hepatic impairment.
Pregnancy/Lactation Contraindicated during the second and third trimesters of pregnancy (must be stopped immediately if detected) and while breastfeeding.
Pediatric Use Not recommended for patients under 18 years; safety and efficacy of the combination are not established in this population.
Haemodynamic Instability Contraindicated in cases of severe hypotension, cardiogenic shock, or obstruction of the left ventricular outflow tract (e.g., severe aortic stenosis).

Conditional use and close monitoring are required for patients with mild to moderate renal impairment, renal artery stenosis, or mild to moderate hepatic impairment. Patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m^2) must not concurrently use aliskiren-containing products with this medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Unisia is a combination of Amlodipine and Candesartan, and its interaction profile combines the risks of both active components as documented in regulatory sources.

Formally Documented Interaction Restrictions

Classification Interacting Substance Official Regulatory Statement
Contraindicated Aliskiren Co-administration is prohibited in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73m²).
Dose Restriction Simvastatin Due to increased exposure caused by Amlodipine, the Simvastatin dose must not exceed 20 mg daily.

Key Interaction Categories

Official regulatory information highlights two main interaction patterns:

  • Exposure-Altering Interactions (Amlodipine): The Amlodipine component, metabolized by CYP3A4, has its systemic exposure significantly increased by strong and moderate CYP3A4 Inhibitors (e.g., Diltiazem, Itraconazole) and reduced by CYP3A4 Inducers (e.g., Rifampin, St. John's Wort). This risk of altered exposure is also noted in patients with hepatic impairment.

  • Pharmacodynamic Risk (Candesartan): The Candesartan component interacts with agents that affect the renin-angiotensin system or electrolyte balance. Co-administration with ACE Inhibitors or NSAIDs increases the risk of renal impairment and hyperkalemia. The risk of hyperkalemia is also increased with Potassium Supplements or Potassium-Sparing Diuretics.

Mechanism of Action

Unisia is a dual kinase inhibitor that acts on two primary enzymatic targets: Glycogen Synthase Kinase-3beta (GSK-3beta) and c-Src. The compound engages with GSK-3beta by directly binding to and inhibiting its catalytic domain, thereby preventing the phosphorylation of its specific substrates. Simultaneously, Unisia functions as a competitive antagonist, binding at the ATP-binding site of c-Src.

Inhibition of GSK-3beta induces an alteration in the phosphorylation state of cytoplasmic signaling molecules, which consequentially reduces the activation of the downstream NF-kappa-B pathway. The combined mechanistic action against both GSK-3beta and c-Src modulates key components of the Wnt signaling cascade. This intracellular and pathway modulation results in a distinct decrease in the differentiation and overall activity of osteoclasts, defining the system-level physiological modulation.

Dosage and Administration Information

How Unisia is Used: Official Administration Guidelines

Unisia is a fixed-dose combination (FDC) tablet containing Amlodipine and Candesartan, and its usage is aligned with the established prescribing profiles for its components.

Official Dosage and Administration

The approved route of administration for Unisia is oral only. The standard adult regimen involves taking one tablet once daily. The specific strength of the combination tablet (such as 8 mg/5 mg of Candesartan/Amlodipine) is chosen to reflect the individually required, stable dose of each component. The tablet may be administered with or without food.

Treatment for essential hypertension is typically long-term and continuous.


Administration for Specific Populations

Established clinical profiles for the components include procedural adjustments for certain patient groups:

  • Hepatic Impairment: Patients with hepatic insufficiency may require a lower initial dose of the Amlodipine component, such as 2.5 mg once daily. A lower starting dose of the Candesartan component (4 mg) is also generally considered for moderate hepatic impairment.

  • Renal Impairment: For patients with renal impairment, a lower starting dose of the Candesartan component (4 mg) is generally utilized.

  • Older Adults: A starting dose of 2.5 mg of the Amlodipine component may be appropriate for small, fragile, or older adult patients.

These guidelines define the necessary strength selection when using the FDC, as the fixed ratio cannot be changed once the tablet is dispensed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Unisia


Evidence Base for Essential Hypertension

The core research for Unisia, which is a fixed-dose combination (FDC) of Amlodipine and Candesartan, has been primarily conducted using randomized controlled trials (RCTs). These studies are the most rigorous type of clinical investigation used to explore specific outcomes. Researchers applied these RCTs studying mostly adults with essential hypertension, including individuals whose high blood pressure was not sufficiently controlled by taking only one component alone.

Studies explored short-term changes in specific physiological measurements, including core biomarkers of high blood pressure: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Findings describe patterns observed in the trials over periods of 8 to 12 weeks, including the proportion of participants whose measurements reached pre-set targets. Comparative evidence also monitored the FDC alongside taking the two components as separate pills.


Long-Term Research and Durability of Control

Research has explored longer-term outcomes, though follow-up durations were limited in the primary research studies. Some evidence is derived from extended observational settings which monitored physiological markers over longer intervals. Scientific literature indicates that patterns of blood pressure measurement were observed over intermediate periods, with some follow-up extending for several years.

However, long-term outcomes on complex markers, such as the incidence of serious cardiovascular events, are not fully characterized specifically for this fixed-dose combination. Data show patterns related to cardiovascular outcomes, but there is limited information because large-scale, dedicated trials designed to specifically compare this FDC against all other combination treatments for cardiovascular event reduction are currently lacking.


Studies in Specific Patient Groups

Evidence for Unisia has been evaluated in various groups, but the results apply only to the specific populations studied. Research described patterns in adult populations, including cohorts of older adults, where the evidence suggests patterns related to the overall observed population. Furthermore, in subgroup analyses, Unisia was evaluated in participants who also had coronary artery disease (CAD). Conversely, data for certain complex groups, such as those with severe kidney or liver impairment, are often insufficient as these individuals were typically excluded from the primary RCTs.

Frequently Asked Questions (FAQ)

Common questions about Unisia (FAQ)


Q: Can Unisia be taken with food?

A: Official administration instructions for Unisia indicate that the medicine may be taken with or without food. This allows for flexibility in scheduling the dose during the day. Consistent administration according to the prescribed schedule is important for managing blood pressure.


Q: Can Unisia make me feel tired?

A: Yes, regulatory documents list fatigue and tiredness among the common side effects associated with the components of Unisia. If persistent or bothersome tiredness is experienced, patients are advised to consult a healthcare professional.


Q: Is it common to have stomach issues with Unisia?

A: Nausea and abdominal pain are noted in the official product information as common side effects of one of the drug's components, Amlodipine. This means that some people may experience these digestive issues, especially when starting the treatment.


Q: Does Unisia interact with common vitamins or supplements?

A: Official drug documents highlight interactions with certain herbal products, such as St. John's Wort, which can change how the Amlodipine component is processed by the body. General vitamins are not typically noted as formal restrictions, but patients are generally advised to inform a healthcare professional about all supplements and medicines they use.


Q: What should I avoid eating or drinking while using Unisia?

A: The Candesartan component interacts with agents that can affect potassium levels; therefore, excessive intake of potassium supplements should be avoided. Additionally, the Amlodipine component may interact with grapefruit products, as they can potentially increase the amount of medicine in your system.


Q: How long does it take for Unisia to clear my system?

A: Official pharmacological data indicates that the half-life (T1/2) of the two components is different. The Candesartan component has a shorter half-life of about 9 hours, while the Amlodipine component is longer-acting, with a half-life ranging from 30 to 50 hours. The half-life refers to the time it takes for the amount of drug in the body to be reduced by half.


Q: Does Unisia require regular blood tests?

A: Due to the potential risk of hyperkalemia (high potassium) and renal impairment associated with the Candesartan component, monitoring of potassium levels and kidney function is generally advised by healthcare professionals.


Q: Does Unisia affect mood or anxiety levels?

A: The official product information lists documented side effects related to central nervous system function, including mood changes, depression, and insomnia. These effects are associated with the Amlodipine component.


Q: Are there known interactions with alcohol and Unisia?

A: Regulatory documents often advise that consuming alcohol may increase the risk of low blood pressure (hypotension) and dizziness. Consultation with a healthcare professional is recommended regarding alcohol use while taking this medication.


Q: Is it normal to feel dizzy when starting Unisia?

A: Yes, dizziness is listed as a common side effect of Unisia. This can occur as the body adjusts to the initial blood pressure-lowering effect of the medicine, particularly when treatment begins.


Q: Does Unisia cause weight gain or loss?

A: Weight changes (either gain or loss) are sometimes reported in official documentation as less common side effects associated with the Amlodipine component. Unexpected changes in weight should be discussed with a healthcare professional.


Q: Can Unisia cause skin rash or itching?

A: Yes, official product information lists skin rash and itching among the less common side effects associated with the components of Unisia. More serious, though rare, skin and swelling reactions are also documented.


Q: How quickly does Unisia start working?

A: The blood pressure-lowering effect typically starts to become noticeable shortly after beginning treatment. The majority of the full intended effect is usually achieved within two weeks after starting the medicine or changing the dose, according to clinical study data.


Q: Is Unisia the same as other medicines in its class?

A: Unisia is a fixed-dose combination (FDC) that contains two active components: Amlodipine (a Calcium Channel Blocke) and Candesartan (an Angiotensin II Receptor Blocker). This two-in-one structure distinguishes it from single-agent medicines or FDCs containing different components.


Q: What happens if I miss a dose of Unisia?

A: According to the official patient information, if a dose is missed, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, you should skip the missed one entirely. Official patient information states not to take two doses to make up for a single missed dose.


Q: Is Unisia addictive or habit-forming?

A: Unisia's active components are an ARB and a CCB, which are drug classes used to manage blood pressure. They are not classified as controlled substances and are not generally considered addictive or habit-forming.


Q: How long can I expect to take Unisia?

A: Treatment for essential hypertension with Unisia is typically considered a long-term and continuous course of therapy. The duration of treatment is determined by a healthcare professional based on ongoing health evaluation.


Q: What should I do if a side effect is bothering me?

A: Consultation with a doctor or pharmacist is advised if a side effect is bothersome or persistent. For serious documented effects, such as severe swelling (angioedema) or chest pain, emergency medical services should be sought.


Q: Is it safe to drive after taking Unisia?

A: Official warnings state that Unisia may affect your ability to drive or use machines. Driving or operating complex machinery should be avoided if side effects such as dizziness, tiredness, or headache occur.


Q: Does Unisia affect sleep?

A: Official regulatory documents indicate that sleeplessness (insomnia) and drowsiness are potential side effects associated with the Amlodipine component of the medicine.


Q: Why is my doctor changing my medication to Unisia?

A: Official information indicates that Unisia is intended for adult patients whose blood pressure is not adequately controlled by taking either Amlodipine or Candesartan alone. This suggests the change is a strategy to achieve better blood pressure control.


Q: Is Unisia a controlled substance?

A: No, the active components of Unisia, Amlodipine and Candesartan, are not scheduled as controlled substances by regulatory agencies.


Q: Are there different strengths of Unisia tablets?

A: Yes, Unisia is available in multiple fixed-dose combinations. These variations combine different amounts of the two components to allow doctors to select a strength that best matches the required dosage of each component.


Q: What were the main findings of the clinical trials for Unisia?

A: Clinical trials found that the fixed-dose combination was associated with a greater reduction in both systolic and diastolic blood pressure compared to taking the individual components alone. These findings supported its use for people whose hypertension was not controlled by monotherapy.


Q: What should I know about stopping Unisia?

A: Consulting a healthcare professional is advised before discontinuing treatment suddenly. Abruptly stopping blood pressure medicine can cause high blood pressure to return or worsen, which is known as rebound hypertension.


Q: Does Unisia change how other medications are absorbed?

A: The Amlodipine component is processed by an enzyme called CYP3A4. Certain other medications that affect this enzyme (inhibitors or inducers) can change the systemic exposure of Amlodipine in the body.


Q: Does Unisia affect my kidney function?

A: The Candesartan component is associated with a risk of renal (kidney) impairment, especially for people with existing kidney issues or when certain interacting medications are also used. Monitoring of kidney function may be necessary during treatment.


Q: Are there specific food types that block Unisia's absorption?

A: Official studies have examined the effect of taking the medicine with meals. Some regulatory documents note that food intake may affect the absorption of the Candesartan component.


Q: Is Unisia safe for people with kidney problems?

A: The use of Unisia requires specific caution and may necessitate a lower starting dose for patients with renal impairment. A healthcare professional determines the appropriateness of Unisia use, as dose adjustments or contraindications apply in cases of renal impairment.


Q: Can I take cold medicine (like Tylenol Cold) with Unisia?

A: Many over-the-counter cold medicines contain components such as NSAIDs (like ibuprofen) or decongestants. These can potentially interact with the Candesartan component, which could increase the risk of kidney issues or interfere with blood pressure control. Consultation with a pharmacist or doctor is advised before using cold medicines while taking Unisia.


Q: How long do the effects of Unisia last after I take it?

A: The medicine is designed for once-daily dosing. The long-acting nature of both components means that the blood pressure-lowering effects are intended to persist for 24 hours to provide consistent control between doses.

How should Unisia be stored and disposed of?

How to Store and Dispose of Unisia?

The storage and disposal of Unisia tablets must strictly comply with the conditions documented in the medicine's official regulatory labeling to ensure its stability.

Mandatory Storage Conditions

Requirement Official Statement
Temperature Store below 30°C (or 25°C, depending on the label). Do not freeze.
Protection Store in the original package to protect the tablets from light and humidity.
Child Safety Keep this medicine out of the sight and reach of children.
Shelf-Life Do not use the medicine after the expiry date (EXP) printed on the carton.

Official Disposal Rules

Unused or expired Unisia must not be thrown away via wastewater or household waste (trash). Disposal must be managed by consulting a pharmacist or following local regulatory requirements to ensure safe handling of the medicinal product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unisia found in:

A-Z Index: